曉鳴股份(300967.SZ)2月銷售收入1.15億元 同比增長208.86%
格隆匯3月10日丨曉鳴股份(300967.SZ)公佈,公司2025年2月銷售雞產品2,724.46萬羽,銷售收入11,545.75萬元,環比變動分別為3.45%、7.88%,同比變動分別為102.61%、208.86%。
2025年2月,受雛雞供需結構偏緊影響,養殖單位補欄積極性依舊較高,雛雞銷售單價相對高位運行,公司雞產品銷售數量、銷售收入同比有較大幅度提升。
2月全國雞蛋價格相對低位運行,主要系春節假期庫存壓力釋放和週期性因素導致,隨着蛋品貿易商採購低價貨源積極性提升,學校開學備貨以及食品廠開工採購量增加,市場供需關係收緊,雞蛋消費情況將陸續好轉。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.